PMID- 32377823
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 258
IP  - 8
DP  - 2020 Aug
TI  - XEN-augmented Baerveldt drainage device implantation in refractory glaucoma: 
      1-year outcomes.
PG  - 1787-1794
LID - 10.1007/s00417-020-04654-3 [doi]
AB  - PURPOSE: To evaluate outcomes of XEN-augmented Baerveldt drainage device 
      implantation in refractory glaucoma and factors predicting surgical success. 
      METHOD: All eyes undergoing XEN-augmented Baerveldt for refractory open-angle 
      glaucoma at a tertiary glaucoma centre between January 2016 and November 2017 
      were retrospectively enrolled. Intraocular pressure (IOP), number of 
      anti-glaucomatous medications and postoperative adverse events (AEs) were 
      analysed for 1 year postoperatively. Surgical success was defined as achieving 
      (1) an IOP </= 15 mmHg or (2) </= 18 mmHg, with or without (qualified) or without 
      medications (complete). Any subsequent glaucoma surgery was considered failure. 
      RESULTS: Out of 60 eyes enrolled, 12-month data were available for 41 eyes 
      (71.4%). Mean age was 64.7 +/- 23.1 years (50% female). Following surgery, IOP 
      decreased significantly from a baseline of 29.9 +/- 13.2 to 15.2 +/- 6.6 mmHg 
      (- 49.2%; P < 0.0001) at 12 months. Anti-glaucoma medications decreased from 
      3.0 +/- 1.3 to 1.3 +/- 0.9. Complete success was achieved by 14.6% of eyes using both 
      the </= 15 mmHg and the </= 18 mmHg thresholds, and qualified success was achieved in 
      43.9% and 48.8%, respectively. Throughout the follow-up period, AEs were observed 
      in 51.2% (hypotony = 24.4%; XEN blockage = 17.1%; displacement of XEN gel 
      stent = 4.9%; hyphema = 4.9%). The 12-month success rate was significantly higher 
      in patients who presented an IOP </= 10 mmHg at 1 week (58.6%, P = 0.001). Overall, 
      41.5% of patients required reoperation at 12 months (58.8% revision of the 
      surgery; 41.2% transscleral cyclodestruction). CONCLUSION: XEN-augmented 
      Baerveldt is a safe and moderately effective technique to reduce IOP and 
      anti-glaucoma medications in refractory glaucoma. IOP at 1 week seems to be a 
      predictor for surgical success. Nevertheless, a high proportion of patients 
      requires reoperation.
FAU - Bravetti, Giorgio Enrico
AU  - Bravetti GE
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Visio, 1006, Lausanne, 
      Switzerland. giorgioenrico.bravetti@gmail.com.
FAU - Mansouri, Kaweh
AU  - Mansouri K
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Visio, 1006, Lausanne, 
      Switzerland.
AD  - Department of Ophthalmology, University of Denver, Denver, USA.
FAU - Gillmann, Kevin
AU  - Gillmann K
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Visio, 1006, Lausanne, 
      Switzerland.
FAU - Rao, Harsha L
AU  - Rao HL
AD  - Narayana Nethralaya, 63, Bannerghatta Road, Hulimavu, Bangalore, India.
FAU - Mermoud, Andre
AU  - Mermoud A
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Visio, 1006, Lausanne, 
      Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
SB  - IM
MH  - Female
MH  - Follow-Up Studies
MH  - Glaucoma/physiopathology/*surgery
MH  - *Glaucoma Drainage Implants
MH  - Humans
MH  - Intraocular Pressure/*physiology
MH  - Male
MH  - Middle Aged
MH  - Ophthalmologic Surgical Procedures/*methods
MH  - Prosthesis Design
MH  - Prosthesis Implantation/*methods
MH  - Retrospective Studies
MH  - *Stents
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Baerveldt's tube
OT  - Glaucoma
OT  - Glaucoma drainage devices
OT  - Glaucoma surgery
OT  - XEN gel stent
EDAT- 2020/05/08 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/11/10 00:00 [received]
PHST- 2020/03/21 00:00 [accepted]
PHST- 2020/02/06 00:00 [revised]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1007/s00417-020-04654-3 [pii]
AID - 10.1007/s00417-020-04654-3 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2020 Aug;258(8):1787-1794. doi: 
      10.1007/s00417-020-04654-3. Epub 2020 May 6.